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OBJECTIVES The study was done to investigate the physiological role of endogenous endothelin-1 in the
human coronary circulation by studying the effect of an intracoronary infusion of the specific
endothelin receptor subtype A (ETA) receptor antagonist BQ123 on coronary vasomotor
tone.
BACKGROUND Endothelin-1 contributes to the maintenance of peripheral vascular tone in humans.
However, its physiological role in the human coronary vasculature is unknown.
METHODS We studied 12 patients (mean age 54.7 6 2.5 years, 3 men) undergoing cardiac catheteriza-
tion for investigation of atypical chest pain, with angiographically normal coronary arteries.
Coronary artery cross-sectional area was measured with digital quantitative coronary
angiography, and coronary blood flow was assessed with an intracoronary Doppler flow wire.
Flow-mediated (adenosine, 18 mg) and agonist-mediated (substance P, 20 pmol/min for
2 min) endothelial responses were measured prior to study. BQ123 (40 nmol/min for 15 min
and monitored for a further 15 min) was infused into the left coronary artery.
RESULTS The BQ123 caused significant dilation of the proximal (artery cross-sectional area: 8.08 6 0.9
to 8.88 6 0.9 mm2; p , 0.05), mid (5.32 6 0.8 to 6.49 6 0.8 mm2; p , 0.001) and distal
study vessel (2.11 6 0.2 to 2.50 6 0.2 mm2; p , 0.05). There was an increase in coronary
blood flow (26.8 6 2.8 to 32.8 6 3.4 ml/min; p , 0.001) but no change in systemic
hemodynamics. Baseline flow- or substance P-induced epicardial vasodilation did not
correlate with the degree of vasodilation induced by BQ123.
CONCLUSIONS These data uncover a role of endogenous endothelin-1 in the maintenance of basal vasomotor
tone in patients with angiographically normal coronary arteries. (J Am Coll Cardiol 2001;37:
137–43) © 2001 by the American College of Cardiology
The 21-amino acid peptide endothelin (ET) was discovered
only 10 years ago (1). It is produced predominantly by
endothelial cells and is the most potent vasoconstrictor
known. Although three ET isoforms have been identified
(ET-1, -2, and -3), ET-1 is the predominant isoform in the
cardiovascular system, acting primarily as an autocrine/
paracrine factor (2). The endothelins have two distinct
receptor subtypes, ETA and ETB, both of which are present
on smooth muscle cells and mediate vasoconstriction via a
variety of subcellular signaling pathways. The ETB receptors
are also present on endothelial cells and are capable of
producing vasodilatation by the local release of
endothelium-derived vasodilators, including nitric oxide
(NO) (3,4).
Studies involving brachial artery administration of the
ETA receptor antagonist BQ123 and the endothelin-
converting enzyme inhibitor phosphoramidon have dem-
onstrated local forearm vasodilation, suggesting that
endogenously produced ET-1 contributes to the physiolog-
ical maintenance of basal vascular tone (4,5). Systemic ETA
and ETB receptor blockade with a 15-min infusion of the
ETA/B receptor antagonist TAK-044 decreased peripheral
vascular resistance and blood pressure, and increased heart
rate, in normal human subjects (6). These results imply that
endogenously produced ET-1 plays an important role in the
tonic maintenance of systemic vascular tone and blood
pressure, in the absence of vascular disease.
The ET-1 isoform has been implicated in the pathophys-
iology of a number of coronary disorders, including myo-
cardial infarction (7), coronary artery spasm (8,9) and
coronary endothelial dysfunction and atherosclerosis (10–
12). The ETA and ETB receptors are expressed on human
coronary smooth muscle (13). However, the precise physi-
ological role of ET in the human coronary circulation
remains unclear. Our aim in this study was to investigate the
physiological role of endogenous ET-1 in patients with
angiographically normal coronary arteries. To avoid con-
founding systemic effects, the study was performed with an
intracoronary infusion of a locally active dose of the selective
ETA receptor antagonist BQ123.
METHODS
The study conformed to the principles outlined in the
Declaration of Helsinki and was conducted with the ap-
proval of the Institutional Research and Ethics Committee.
All subjects provided written informed consent.
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We studied 12 patients (3 men, mean age 54.7 6 2.5
years) undergoing diagnostic cardiac catheterization for the
investigation of atypical chest pain. None had diabetes or
clinical/electrocardiographic (ECG) features of coronary
spasm or syndrome X. Patients with valvular heart disease,
left ventricular hypertrophy and left ventricular dysfunction
were excluded by echocardiography prior to study. All
medications were withheld and all subjects abstained from
alcohol, caffeine-containing drinks, and cigarettes for at
least 24 h, and from food for at least 6 h before cardiac
catheterization. Patient characteristics are shown in Table 1.
Cardiac catheterization was performed via the right
femoral approach in a quiet, temperature-controlled cardiac
catheterization laboratory, using biplane digital cineangiog-
raphy (Philips Optimus 2000). After diagnostic coronary
angiography, 10,000 iU of heparin was given, and a 7F
Judkins guiding catheter was introduced into the left main
coronary artery. A 3F infusion catheter (Boston Scientific)
was advanced over a 0.014-in. (0.0356-cm) Doppler flow-
velocity guide wire (Cardiometrics, California) and posi-
tioned in a nonbranching segment of the mid-left anterior
descending coronary artery (LAD, n 5 11) or circumflex
coronary artery (Cx, n 5 1). The Doppler wire was then
manipulated ;1 cm distal to the tip of the infusion catheter
into a position that gave a stable velocity signal. The
Doppler wire was interfaced with a real-time spectral
analysis system (FlowMap, Cardiometrics, California) to
enable recording of the average peak (Doppler) velocity
(APV) of blood flow. Coronary blood flow was calculated by
multiplying one-half of this value by the coronary artery area
at the tip of the Doppler flow wire on the corresponding
angiogram. The technique was identical to that used in a
previous study (14), and the accuracy of this system has been
verified in a separate publication (15). Adenosine was
administered selectively into the coronary artery via the
infusion catheter, but all other drugs were administered
through the guiding catheter.
Study protocol. We assessed endothelial function (both
epicardial dilation following an increase in coronary flow
induced by adenosine and agonist-mediated vasodilation) in
all patients prior to BQ123 infusion. An 18 mg bolus of
adenosine was given via the infusion catheter, and angio-
grams were taken 30 s after the resultant peak APV. This
protocol for assessing flow-mediated dilation is similar to
that used in a previous study (14), and adenosine in a
bolus dose of 18 mg has been shown to achieve adequate
coronary vasodilation for this purpose (16). Substance P
(20 pmol/min for 2 min; dissolved in 0.9% saline) was used
to assess agonist-mediated vasodilation. This agent appears
to be more selective than acetylcholine in modulating
vascular tone by the release of NO; furthermore, it does not
directly affect smooth muscle tone (17,18). The dose-
response relationship for substance P-induced in vivo epi-
cardial coronary vasodilation in humans has been well
characterized (19). Endothelium-independent dilation was
also assessed as the response to intracoronary glyceryl
trinitrate (GTN) (250 mg bolus) at the end of the study
protocol.
The BQ123 (American Peptide, Sunnyvale, California)
was infused into the left coronary artery at a dose of 40
nmol/min (flow rate 2 ml/min; dissolved in 0.9% saline) for
15 min, using an IVAC P4000 anesthesia syringe pump
(Welmed, Hampshire, United Kingdom). Previous studies
by Verhaar et al. (4) have shown that an infusion of 10
nmol/min BQ123 in the human forearm induced maximal
vasodilatation, yet remained locally active (i.e., blood flow
was unchanged in the noninfused forearm). We chose a
dose of 40 nmol/min to achieve a roughly equivalent local
concentration (;0.4 mmol/liter, assuming a maximum total
Abbreviations and Acronyms
APV 5 average peak (Doppler) velocity
Cx 5 circumflex coronary artery
ET 5 endothelin
ETA/ETB 5 endothelin receptor subtype A/B
GTN 5 glyceryl trinitrate
LAD 5 left anterior descending coronary artery
NO 5 nitric oxide
Table 1. Clinical Characteristics of the Patients
Patient
Age
(yrs) Gender
Vessel
Studied
Total
Cholesterol
(mmol/liter)
Triglycerides
(mmol/liter) Hypertension Smoker
FHx of
Vascular
Disease
1 67 M LAD 4.2 2.2 1 2 1
2 52 M LAD 6 1.8 2 1 2
3 49 F Cx 5.8 1.1 1 2 1
4 53 F LAD 7.1 1.2 2 2 1
5 45 F LAD 9.2 4 2 2 2
6 56 F LAD 6.2 1.2 2 2 2
7 57 F LAD 8.6 3 1 2 2
8 58 F LAD 6.6 1.6 1 2 1
9 74 F LAD 8 2.2 2 2 2
10 50 M LAD 5.2 3.2 1 2 2
11 50 F LAD 5.5 2.7 2 1 1
12 45 F LAD 9.0 3.1 1 2 1
Cx 5 circumflex coronary artery; FHx 5 family history; LAD 5 left anterior descending coronary artery.
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coronary flow rate of approximately 100 ml/min). This
concentration is 10- to 100-fold higher than the reported
affinity of binding sites for BQ123 in human coronary
vascular smooth muscle (Kd 0.85 nmol/liter) (13), yet still
selective for the ETA receptor (13,20,21). The study pro-
tocol is shown in Figure 1.
An infusion of normal saline at 2 ml/min was substituted
between drug administrations. Recordings of a biplane
angiogram, Doppler APV, aortic pressure and ECG were
obtained after each drug administration.
Quantitative coronary angiography. Serial angiograms
with nonionic contrast medium (Omnipaque) were per-
formed in each patient using a biplanar radiographic system
with the study artery positioned near the isocenter and
avoiding vessel overlap. The angle of projection was set at
the beginning of the protocol and was not altered thereafter.
Digital analysis was performed off-line with an edge-
detection system (EasyVision, Philips) using a previously
described and validated method (14,22,23). For each angio-
gram, diameter measurements were made (using geometric
edge detection) from three end-diastolic frames and aver-
aged. In each frame, mean vessel diameter was measured in
the proximal, mid- and distal study vessel in both views of
the biplanar angiogram, using side branches, the infusion
catheter, and Doppler flow wire tip as anatomic landmarks.
Cross-sectional arterial area was calculated on the assump-
tion of an elliptical lumen.
Statistics. Data are expressed as mean 6 SEM. Values for
coronary artery cross-sectional area and coronary blood flow
before and after adenosine, substance P and GTN were
compared with paired t-tests. Similar values before, imme-
diately after BQ123 infusion and 15 min after discontinu-
ation of BQ123 were compared with one-way analysis of
variance (ANOVA) for repeated measures with Tukey post
hoc testing, using a statistical software package (Statview™
version 4.5). All analyses were two-tailed, and a value of p ,
0.05 was considered to indicate statistical significance.
RESULTS
There were no complications in any of the patients studied,
and no adverse effects to BQ123 were observed. No signif-
icant change occurred in heart rate, ECG or aortic pressure
in any patient after any of the drugs were administered.
Changes in arterial cross-sectional area. Infusion of
BQ123 led to significant vasodilation in all segments of the
study vessel (i.e., proximal, mid and distal) at the end of the
infusion (Fig. 2). This change was most marked in the mid
study vessel, in which the artery cross-sectional area in-
creased by 24.3 6 4.9% (mean 5.32 6 0.8 mm2 to 6.49 6
0.8 mm2, p , 0.001). The cross-sectional area in the distal
vessel increased by 22.3 6 8.6% (mean 2.11 6 0.2 mm2 to
2.50 6 0.2 mm2, p , 0.05); in the proximal vessel, the
increase was 10.7 6 3.9% (mean 8.08 6 0.9 mm2 to 8.88 6
0.9 mm2, p , 0.05). This vasodilation had diminished by
15 min post-BQ123 infusion in the mid- and distal vessel
(to 5.95 6 0.9 mm2 and 2.38 6 0.2 mm2, respectively; p 5
NS), but remained significantly greater than baseline in the
proximal vessel (9.10 6 0.9 mm2; p , 0.05).
Changes in coronary flow. Following BQ123 infusion,
coronary flow increased significantly (Fig. 3) by 24.3 6
5.1% (mean 26.8 6 2.8 ml/min to 32.8 6 3.4 ml/min; p ,
0.001). Coronary flow had returned to 30.0 6 3.3 ml/min
by 15 min post-BQ123 infusion, which was not significantly
greater than at baseline.
Endothelial function. Of the 12 patients studied, 11 had
vasodilatory responses to flow- and agonist-mediated stim-
uli. All 12 responded to the endothelium-independent
Figure 1. Schematic representation of experimental protocol. B 5 baseline measurements; A 5 angiogram; F 5 Doppler flow-wire measurement;
H 5 hemodynamic measurements, including blood pressure, heart rate, and ECG.
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stimulus of GTN (mean data shown in Table 2). One
patient (Patient 5) failed to exhibit epicardial vasodilation in
response either to an increase in coronary flow induced by
adenosine or to substance P, but nevertheless did show a
vasodilatory response to BQ123. If this patient had been
excluded from analysis, the effect of BQ123 on mid study
vessel cross-sectional area and coronary flow remained
highly significant. No correlation was found between the
magnitude of epicardial vasodilator response to flow (aden-
osine) or agonist (substance P) and the epicardial vasodila-
tory response to BQ123 in individual patients (r 5 0.54 and
20.01, respectively; both p 5 NS). There was no correla-
tion between changes in coronary flow induced by substance
P and those induced by BQ123 (r 5 20.30, p 5 NS), nor
was there a correlation between serum cholesterol and
vasodilator response to BQ123 (r 5 20.02; p 5 NS).
DISCUSSION
We have shown that selective blockade of ETA receptors in
humans with angiographically normal coronary arteries
causes vasodilation of the epicardial vessels and an increase
in coronary blood flow. These data imply for the first time
that endogenous ET plays an important physiological role
in the regulation of vasomotor tone in human conduit and
resistance coronary vessels. Our results demonstrate that the
previous findings of a role for endogenous ET in peripheral
arteries in humans (5,24) can now be extended to the
normal human coronary vasculature.
Previous studies by Haynes et al. (5) showed that brachial
artery infusion of BQ123 caused progressive vasodilation,
increasing forearm blood flow by 64% at 60 min in normal
human subjects, while administration of the ET-converting
enzyme inhibitor phosphoramidon had similar effects. In
animal studies, systemic BQ123 administration lowered
blood pressure, suggesting that this tonic effect of ET is
present in vascular beds other than just the forelimb (25).
Intracoronary administration of the selective ETA antago-
nist Ro-61-1790 in conscious dogs caused epicardial coro-
nary vasodilation (26). The physiological effects of ET in
the human coronary circulation, however, have remained
unknown. From previous studies it is apparent that re-
sponses to ET receptor antagonists vary, depending on
species, vascular bed and presence of vascular disease. It
cannot therefore be assumed that ET has similar physio-
logical importance in different vascular beds.
In a recent study, Wenzel and colleagues (27) assessed
Figure 2. Mean cross-sectional artery area at baseline, at the end of the 15-min BQ123 infusion (peak BQ123) and 15-min post-BQ123 infusion, in the
proximal, mid and distal study vessel. Lower panels show percentage change from baseline. *p , 0.05; **p , 0.001 vs. baseline.
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coronary vasomotor tone after the systemic IV administra-
tion of the ETA/B receptor antagonist bosentan in patients
with angiographically documented coronary artery disease.
These investigators reported an increase in epicardial coro-
nary artery diameter after bosentan, an effect that was seen
particularly in arterial segments in which there was little
angiographic evidence of atherosclerotic disease and which
correlated inversely with plasma low density lipoprotein
(LDL)-cholesterol levels. In contrast to the present study,
no change in coronary flow was detected. However, the data
are difficult to interpret because bosentan was given system-
ically (intravenously) and resulted in a decrease in systolic
blood pressure and an increase in heart rate. These systemic
effects may have secondarily affected coronary vasomotor
tone, although such confounding effects would have affected
both the patients with normal coronary arteries and those
with coronary artery disease. Baseline endothelial function
was also not assessed, so that no conclusions could be drawn
about the relationship between the effect of ET and the
functional integrity of the endothelium. It is important to
note that both the generation of and response to endoge-
nous ET may change in the presence of coronary disease
and endothelial dysfunction. Under these circumstances,
impaired NO production, for example, may attenuate dila-
tor responses of ETB receptors and promote constrictor
responses via ETA receptors (28).
In the current study, we selected patients without angio-
graphic evidence of coronary artery disease, 11 out of 12 of
whom demonstrated endothelial vasodilator responses. Fur-
thermore, we used a specific ETA-receptor antagonist that
was selectively infused into the coronary artery at a dose
that did not give rise to systemic effects so as to ensure that
observed changes in coronary tone were not confounded by
alterations in systemic hemodynamics. Epicardial vasodila-
tion was observed in the proximal, mid and distal study
vessel at the end of BQ123 administration, and these effects
were largely reversed 15 min after discontinuing the infu-
sion. The vasodilatory effects of BQ123 appeared to be
consistently greater in the mid and distal vessel. This
differential effect may be explicable by the distribution of
ETA receptors in human coronary arteries. In vitro studies
have shown that ETA receptors mediate contractile re-
sponses in distal, pre-resistant human epicardial coronary
arteries, whereas other ET receptor types are involved in
constriction of more proximal vessel segments (29).
The mechanism by which ETA receptor blockade with
BQ123 leads to coronary vasodilation is speculative and
potentially complex. It is possible that the effects were due
to the removal of a tonic vasoconstrictive effect of endoge-
Figure 3. Mean values for study vessel blood flow at baseline, at the end of
the 15-min BQ123 infusion (peak BQ123) and 15-min post-BQ123
infusion. Lower panel shows percentage change from baseline. *p , 0.001
vs. baseline.
Table 2. Arterial Cross-Sectional Area and Coronary Flow at Baseline and After Flow-Mediated
(Adenosine) and Agonist-Mediated (Substance P) Vasodilation and Endothelium-Independent
(GTN) Vasodilation
Study Vessel Cross-Sectional Area (mm2)
Flow
(ml/min)Proximal Mid Distal
Baseline 7.99 6 0.80 5.64 6 0.82 2.28 6 0.21 31.7 6 3.8
Flow-mediated dilation 9.58 6 1.02* 6.78 6 0.90† 2.91 6 0.28† 91.0 6 15.1
Agonist-mediated dilation 9.54 6 1.00 6.92 6 0.87 2.82 6 0.32 41.6 6 3.9
Endothelium-independent dilation 9.98 6 1.17 7.41 6 0.99 3.21 6 0.35 48.2 6 7.6
All values for flow-mediated, agonist-mediated and endothelin-independent dilation are significantly greater than their
respective baseline values (p , 0.05). *Vasodilator effect mediated by an increase in study vessel blood flow; †vasodilator effect
mediated by local adenosine administration.
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nous ET-1 at the ETA receptor, although ET-1 binds
tightly to the ETA receptor and it is therefore unlikely that
ET is displaced by BQ123. The agonist-receptor complex is
rapidly internalized and ET antagonists probably inhibit
unoccupied and/or newly expressed surface receptors (30).
Whatever the mechanism, excess ET-1 may be available to
act unopposed on ETB receptors, leading to the increased
release of endothelium-dependent vasodilators. In the hu-
man forearm, the vasodilatory effects of BQ123 were atten-
uated by inhibition of endogenous NO synthesis, implying
that BQ123 unmasks the ETB/NO-mediated vasodilator
effect of endogenous ET-1 (4). The fact that maximal local
ETA receptor antagonism caused more vasodilation than
maximal local ETA/B antagonism (5,6) also corroborates the
likelihood that an important component of the BQ123
vasodilator effect may be ETB receptor-mediated. Endoge-
nous ET-1 activity is therefore likely to depend on a complex
balance of ETA and ETB-mediated effects with factors such as
receptor density and functional endothelial integrity influenc-
ing responses to different receptor antagonists.
Endothelin-1 has been implicated in the pathophysiology
of a wide range of vascular diseases, including hypertension
(28,31), coronary artery spasm (8,9), atherosclerosis (both
early [10] and advanced [11]), myocardial infarction (7) and
heart failure (32). It is known that ET can act as a mitogen,
enhancing the growth of vascular smooth muscle cells (33),
and it plays a role in neointima formation after arterial
injury (34). There is therefore much interest in the potential
therapeutic applications of ET receptor antagonists. In a
recent clinical study (35), oral bosentan decreased blood
pressure in patients with essential hypertension to a similar
degree as the angiotensin-converting enzyme (ACE) inhib-
itor enalapril, while the IV administration of bosentan led to
a fall in mean arterial and pulmonary artery pressure in
patients with heart failure (36). The results of the present
study illustrate the potentially beneficial coronary vasodila-
tory effects of ETA receptor antagonists, although the
importance of these effects in disease states requires further
investigation.
Study limitations. A number of limitations of our study
merit discussion. First, our data probably underestimate the
magnitude of the BQ123 effect, as previous studies in the
peripheral vasculature have shown that this antagonist has a
progressive action for up to 60 min (4,5). Prolonged invasive
monitoring was not feasible in this study, however, for
ethical reasons. Significant responses to ET antagonists
have been found, however, in other animal and human
studies (4–6,37), within 15 min of infusion. Second, we
only used a single agent, ETA receptor antagonist, and
therefore can make no conclusions about the mechanism of
the vasodilator response to BQ123 or the role of ETB
receptors. Finally, several of our patients had risk factors for
endothelial dysfunction (Table 1) and one patient did not
have any flow- or agonist-mediated vasodilator response. It
is therefore possible that the effect of intracoronary BQ123
might be different in subjects without any cardiovascular risk
factors (38), but such individuals rarely come to cardiac
catheterization. However, we found no correlation between
the magnitude of epicardial vasodilator response to flow- or
agonist-mediated stimuli and the vasodilator response to
BQ123, suggesting that the presence of cardiovascular risk
factors did not significantly influence the present results.
Summary. In this study, we have demonstrated that the
ETA receptor antagonist BQ123 causes significant coronary
vasodilation in the absence of angiographic coronary artery
disease, implying for the first time that endogenous ET-1 is
important in the physiological regulation of basal coronary
vasomotor tone. The precise mechanisms of the physiolog-
ical role of ET-1, the receptors via which it is mediated, and
the extent to which these effects are altered in disease states
require further investigation.
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